Gene therapies need new development models

Fulvio Mavilio ()
Additional contact information
Fulvio Mavilio: Fulvio Mavilio is scientific director of Genethon in Evry, France, and a professor of molecular biology at the University of Modena and Reggio Emilia in Italy.

Nature, 2012, vol. 490, issue 7418, 7-7

Abstract: As with other medicines, the approval of gene therapies should hinge on a risk–benefit analysis for the patient, argues Fulvio Mavilio.

Date: 2012
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/490007a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:490:y:2012:i:7418:d:10.1038_490007a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/490007a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().